"We plan to analyze these MRI structural measures longitudinally to determine if changes in brain volumes or lesion burden over time contribute to fatigue trajectories. More broadly, we might ...

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MRI paramagnetic rim lesions are associated with ...

Brain lesions — areas of brain tissue that show damage from injury or disease — are the biomarker most widely used to determine multiple sclerosis disease progression. But an innovative new study led ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fenebrutinib met primary and secondary endpoints in ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Prospective tracking of "smoldering" chronic active lesions with notable darkened rims in people with multiple sclerosis (MS), previously only detectable upon autopsy, suggests the lesions are linked ...

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...

– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to ...

The Swoop portable MRI system showed 92% agreement with traditional MRI scans and was four times more likely to be chosen by patients.